METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION

Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION explained in plain language.

Never miss a new study

Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION trials appear

Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for hard-to-treat prostate cancer? drug targets genetic flaw

Disease control Recruiting now

This study tests the drug bortezomib in 22 men with a specific genetic change (PTEN deletion) in their advanced prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the drug can lower PSA levels by at least 30%. Participants receive bortezomi…

Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION

Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control

Last updated Jun 12, 2026 12:05 UTC

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION

Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION trials appear

New hope for hard-to-treat prostate cancer? drug targets genetic flaw